Journal
INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 16, Issue -, Pages 4373-4390Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S305851
Keywords
Alzheimer's disease; AD; nose-to-brain delivery; nanoemulsions; nanostructured lipid carriers; NLC; in situ hydrogels
Funding
- Fundacao para a Ciencia e a Tecnologia (FCT) Portugal [SFRH/131074/2017]
- Applied Molecular Biosciences Unit - UCIBIO - FCT [UIDP/04378/2020, UIDB/04378/2020]
Ask authors/readers for more resources
Treatment for Alzheimer's disease focuses on slowing symptom progression and enhancing quality of life. Nasal delivery offers a potential alternative route to directly deliver drugs to the brain, but clearance mechanisms in the nasal cavity hinder drug delivery efficiency. Formulations of lipid-based nanosystems show promise in optimizing nose-to-brain drug delivery, minimizing side effects, and maximizing therapeutic benefits.
Current treatments for Alzheimer's disease (AD) attenuate the progression of symptoms and aim to improve the patient's quality of life. Licensed medicines are mostly for oral administration and are limited by the difficulty in crossing the blood-brain barrier (BBB). Here in, the nasal route has been explored as an alternative pathway that allows drugs to be directly delivered to the brain via the nasal cavity. However, clearance mechanisms in the nasal cavity impair the delivery of drugs to the brain and limit their bioavailability. To optimize nose-to-brain delivery, formulations of lipid-based nanosystems, namely nanoemulsions and nanostructured lipid carriers (NLC), formulated in situ gelling hydrogels have been proposed as approaches for nose-to-brain delivery. These formulations possess characteristics that facilitate drug transport directly to the brain, minimizing side effects and maximizing therapeutic benefits. It has been recommended that the manufacture of these drug delivery systems follows the quality by design (QbD) approach based on nasal administration requirements. This review provides an insight into the current knowledge of the AD, highlighting the need for an effective drug delivery to the brain. Considering the mounting interest in the use of nanoemulsions and NLC for nose-to-brain delivery, a description of drug transport pathways in the nasal cavity and the application of these nanosystems and their in situ hydrogels through the intranasal route are presented. Relevant preclinical studies are summarised, and the future prospects for the use of lipid-based nanosystems in the treatment of AD are emphasized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available